Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul 10;12(7):e0181103.
doi: 10.1371/journal.pone.0181103. eCollection 2017.

Cancer-selective, single agent chemoradiosensitising gold nanoparticles

Affiliations

Cancer-selective, single agent chemoradiosensitising gold nanoparticles

Sophie Grellet et al. PLoS One. .

Abstract

Two nanometre gold nanoparticles (AuNPs), bearing sugar moieties and/or thiol-polyethylene glycol-amine (PEG-amine), were synthesised and evaluated for their in vitro toxicity and ability to radiosensitise cells with 220 kV and 6 MV X-rays, using four cell lines representing normal and cancerous skin and breast tissues. Acute 3 h exposure of cells to AuNPs, bearing PEG-amine only or a 50:50 ratio of alpha-galactose derivative and PEG-amine resulted in selective uptake and toxicity towards cancer cells at unprecedentedly low nanomolar concentrations. Chemotoxicity was prevented by co-administration of N-acetyl cysteine antioxidant, or partially prevented by the caspase inhibitor Z-VAD-FMK. In addition to their intrinsic cancer-selective chemotoxicity, these AuNPs acted as radiosensitisers in combination with 220 kV or 6 MV X-rays. The ability of AuNPs bearing simple ligands to act as cancer-selective chemoradiosensitisers at low concentrations is a novel discovery that holds great promise in developing low-cost cancer nanotherapeutics.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: Our commercial affiliation with Midatech Pharma involved them providing coated gold nanoparticles and performing some of the physical characterisation of these nanoparticles. Our commercial affiliation with GenesisCare involved using their radiotherapy equipment to irradiate samples. These affiliations with Midatech Pharma and GenesisCare do not alter our adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. Clonogenic assay dose-response curves for three different 50:50 sugar:PEG-amine AuNPs on adherent HSC-3 and HaCaT cells.
Cells were loaded with a range of AuNP concentrations for: A) 1 h, B) 3 h, C) 6 h and D) 24 h. The graphs represent the percentage of cell colonies compared to the no-nanoparticle control for each sugar:PEG-amine AuNP ±SEM.
Fig 2
Fig 2. Clonogenic assay dose-response of different ratios of αGal:PEG-amine AuNPs, citrate-capped AuNPs, αGal only, or PEG-amine only, loaded for 3 h on adherent cells.
a) HSC-3 cells, b) HaCaT cells. The graphs represent the percentage of cell colonies compared to the no-nanoparticle control ±SEM.
Fig 3
Fig 3. Amount of gold per cell (left axis) in HSC-3 cells and HaCaT cells loaded with the HSC-3 IC50 (suspension culture) concentrations of different αGal:PEG-amine AuNPs for 3 h.
IC50 loading concentration (right axis) plotted as dotted line. Inset shows the same data re-plotted as gold per cell divided by AuNP loading concentration. All data are presented as mean value ± SEM.
Fig 4
Fig 4. TEM images of A,B) HSC-3 and C,D) HaCaT cells incubated for 3 h with 10 μg/ml 50:50 αGal:PEG-amine AuNPs.
Boxed areas in A and C are magnified in B and D, respectively. Arrows indicate AuNPs within cytoplasm; n, nucleus; m, mitochondrion; scale bars A,C are 500 nm; B,D are 100 nm.
Fig 5
Fig 5. TEM images of A,B) HSC-3 and C,D) HaCaT cells incubated for 3 h with 10 μg/ml 0:100 αGal:PEG-amine AuNPs.
Boxed area in A is shown magnified in B. Scale bars A,C are 500 nm; B,D are 100 nm.
Fig 6
Fig 6. Clonogenic assay of HSC-3 cells exposed to 1 μg/ml 50:50 αGal:PEG-amine AuNPs in presence or in absence of 0.1 mM sodium pyruvate (NaPy) or 1 mM N-acetylcysteine (NAC) antioxidants.
For each condition, n = 3 and data are presented ±SEM. **** Denotes a significant difference (P<0.0001 ANOVA, Tukey multiple comparisons post-test).
Fig 7
Fig 7. Clonogenic assay of HSC-3 cells, demonstrating a partial rescue of 50:50 αGal:PEG-amine AuNP-induced cell death by 50 μM Z-VAD-FMK caspase inhibitor.
10 μM Antimycin A was used as an apoptosis positive control. For each condition, n = 3 and data are presented ±SEM. * Denotes a significant difference (P<0.05 ANOVA, Tukey multiple comparisons post-test).
Fig 8
Fig 8. Hydroxyl radical formation assay of three different 6 μg/ml AuNP preparations in water with or without exposure to 10 Gy of A) 6 MV X-rays or B) 220 keV X-rays.
Significant differences in fluorescence of 7-OHCCA probe following irradiation, compared to irradiated water only are indicated as P<0.05 *, P<0.01 **, P<0.001 *** (ANOVA with Dunnett’s multiple comparisons post test).
Fig 9
Fig 9. Normalised survival fractions of (A,C) HSC-3 and (B,D) HaCaT cells following exposure to αGal:PEG-amine AuNPs at their HSC-3 IC50 concentrations, followed by different doses of (A,B) 220 kV X-rays or (C.D) 6 MV X-rays.
Data are presented as the mean survival fraction ±SEM. A linear-quadratic curve was fitted to each data series.
Fig 10
Fig 10. Clonogenic assay dose-response of adherent MCF-7 and MCF-10 cells exposed for 3 h to different concentrations of 50:50 or 0:100 αGal:PEG-amine AuNPs.
The graphs represent the percentage of cell colonies compared to the no-nanoparticle control ±SEM.
Fig 11
Fig 11. Clonogenic assay of (A,B) MCF-7 and (C,D) MCF-10 cells following exposure to αGal:PEG-amine AuNPs at their MCF-7 IC50 concentrations, then different doses of A,C) 220 kV X-rays or B,D) 6 MV X-rays.

References

    1. Kwatra D, Venugopal A, Anant S. Nanoparticles in radiation therapy: a summary of various approaches to enhance radiosensitization in cancer. Transl Cancer Res. 2013;2: 330–342.
    1. Pottier A, Borghi E, Levy L. The future of nanosized radiation enhancers. Br J Radiol. British Institute of Radiology; 2015;88: 20150171 doi: 10.1259/bjr.20150171 - DOI - PMC - PubMed
    1. McMahon SJ, Paganetti H, Prise KM. Optimising element choice for nanoparticle radiosensitisers. Nanoscale. 2016; doi: 10.1039/C5NR07089A - DOI - PubMed
    1. McMahon SJ, Hyland WB, Muir MF, Coulter JA, Jain S, Butterworth KT, et al. Biological consequences of nanoscale energy deposition near irradiated heavy atom nanoparticles. Sci Rep. Nature Publishing Group; 2011;1: 18 doi: 10.1038/srep00018 - DOI - PMC - PubMed
    1. Hainfeld JF, Dilmanian FA, Slatkin DN, Smilowitz HM. Radiotherapy enhancement with gold nanoparticles. J Pharm Pharmacol. Blackwell Publishing Ltd; 2008;60: 977–985. doi: 10.1211/jpp.60.8.0005 - DOI - PubMed

LinkOut - more resources